Fierce New Product Planning 2024

Forecasting in large organisations faces a number of challenges that go beyond the forecast itself. The bigger the number of stakeholders and assets, the bigger the need for assumption consistency and transparency and alignment on an agreed forecasting process. As much as Excel is capable of supporting very complex forecasting models, additional layers of functionality are required to meet the operational and organisational challenges in this situation. In absence of an obvious gold-standard, which strategies do different types of organisations pursue to make the forecasting process most efficient?
 
It appears that the topics of IRA and the impact of AI rank high in influencing forecasting both near term and long term. How do forecasters deal with the impact and uncertainties around the IRA? Where do experienced forecasters see the most opportunity for AI to either improve forecast accuracy, help with demand planning or support insightful analytics?
 
Join our panel of experienced forecasting professionals to discuss the above questions and hear their vision of the future in forecasting.

Explore the transformative potential of generative AI in enhancing market and competitive intelligence workflows, delivering faster and more accurate insights. This presentation will provide an overview of cutting-edge AI technologies, including Large Language Models (LLMs) and AI Agents, and their practical applications for understanding R&D pipelines and bringing treatments to market.

Key Topics Include:

1. Generative AI and AI Agents: Transforming market analysis and forecasting
2. Advanced AI tools: Smarter data extraction 
3. AlphaSense: The largest source of equity research and clinical trial reports
4. Gen AI: Risks and benefits ahead
   
   AlphaSense, an AI-powered market intelligence platform, enables executives to make confident, data-driven decisions with unparalleled speed. With the industry’s most comprehensive collection of equity research alongside company presentations and clinical trial data, AlphaSense delivers robust solutions for drug pipeline analysis, forecasting, and due diligence.
   
   

This panel will provide a comprehensive examination of the evolving landscape of market access and pricing strategies in the wake of the Inflation Reduction Act (IRA), featuring insights from experts across the pharmaceutical industry.

• Disrupting the Status Quo - Panelists will explore how the IRA fundamentally shifts the balance of power in pharmaceutical pricing and market access, highlighting the strategic challenges and opportunities for companies navigating Medicare Part D changes.
• Strategies for adapting business models under the IRA, focusing on new pricing strategies, transparency, and innovation within fiscal constraints.
• An examination of the IRA's impact on innovation and smaller biotech firms, addressing funding, investment, and regulatory challenges.
• Discussion on international market trends and their influence on drug pricing and access strategies.
• Effective strategies for engaging with payers to enhance drug accessibility and affordability in the context of new global policies and economic pressures.

Asset development is often highly centered around obtaining regulatory approval. This clinically-minded lens puts market adoption at risk. In this session, we’ll discuss how new approaches to asset development which wholistically integrate both clinical and commercial considerations can de-risk development costs, maximize uptake, and help support a better value creation narrative for investors or other key stakeholders. We’ll look at a case study of how an early stage biotech used this approach to successfully prove their asset’s worth, secure capital, and advance development. Join us as we share with you our thoughts on Rethinking Asset Development: The Power of Commercial Insights.

• Explore strategies for enhancing integration and communication between R&D, clinical, and commercial teams.
• Discuss the importance of aligning these teams early in the development process to ensure successful asset progression.
• Share case studies demonstrating successful cross-functional collaboration and its impact on project outcomes.

• We will emphasize the necessity of early positioning in the drug development process and its cross-functional nature.
• Discuss the common mistake of late positioning and the benefits of integrating positioning strategies before designing phase three trials.
• Hear real-world examples to illustrate the impact of early positioning on product success.
• Understand how early positioning is a critical precursor to a successful product launch, avoiding rigid phase three protocols that limit strategic flexibility.
  

As Medicare’s Maximum Fair Prices (MFPs) for the first ten selected drugs have finally been released, IRA is again at the forefront of forecasting, market access, patient services, and BD/portfolio strategy teams' minds as they grapple with the future prospects of their lead development programs. Strategically setting price and cost of access as assets approach launch is no longer enough to realize the full value of a program – teams must now consider how to maximize value even as they select candidates for clinical development. Join Triangle Insights Group for an interactive presentation where our Pricing and Market Access and New Product Planning leadership outlines potential approaches to maximize near-term ROI and long-term revenue potential in the age of IRA drug pricing provisions, including:

• A general overview of key updates to IRA drug pricing provisions from the most recent guidance
• The evolution of strategies for candidate selection and development in the context of the IRA drug pricing provisions
• An interactive product profile selection and design process based on characteristics favorable to the IRA landscape

Delve into the strategic importance of Target Product Profiles (TPPs) in pharmaceutical development with a panel of industry experts. This discussion will explore advanced strategies, key considerations, and real-world applications of TPPs to optimize drug development outcomes.

• Discuss the role of TPPs in facilitating smoother regulatory reviews and negotiations, and preparing for market access challenges.
• Strategies for updating TPPs in response to new clinical data, regulatory feedback, and changes in the competitive landscape to keep the development process agile.
• Real-World Applications: Analyze case studies that highlight both successful implementations and common pitfalls of TPPs in drug development, offering practical insights and actionable strategies.

Join us for an exciting and interactive session where we reveal the top three value-added oncology programs, identified through our research study with oncologists and payers. These insights are essential for pharmaceutical companies looking to enhance their product offerings.

What to Expect:

• Industry Perspectives: Ray Gomez, who has spearheaded transformations at leading pharmaceutical companies like Bristol Myers Squibb and Novartis, will provide expert commentary and industry insights.
• Get Past 'Planning' – See Tangible Examples: Sherif Salti, Founder and Global Managing Partner of SALTI, will showcase the top three customer engagement journeys that stand out based on our research.
• Interactive Experience: This session isn’t just a presentation—you’ll have the chance to ask questions, share ideas, and see real examples in action.
  
  

Come ready to engage, learn, and walk away with clear, actionable steps to elevate your new product planning strategies in oncology.

Michelle Robertson, EVP, CFO and Treasurer of Geron, will present a case study on how to prepare a company for the transition from a clinical development to a commercial organization based on her experiences launching a first-of-its-kind medicine.

In June 2024, Geron received FDA approval for RYTELO™ (imetelstat), the first-ever telomerase inhibitor, for the treatment of certain adults with lower-risk MDS with transfusion-dependent anemia, following a multi-decade scientific and drug development journey to bring the potential of telomerase inhibition to patients. Key takeaways will include how and where to invest your resources; mitigating risks as a company doubles in size; and making strategic investments to set your company up for success.

• Best practices to maximize capital use and minimize waste across development phases and launch.
• Flexible and robust budgeting techniques that adapt to unexpected changes and regulatory shifts in development.
• Long-term financial strategies that align with business goals and maintain investor confidence. 

• Better prepare your organization to effectively evaluate the commercial potential of early-stage assets and have greater confidence in the key strategic decisions you need to make for your early pipeline
• Reimagine the traditional prioritization of activities when exploring a new asset’s viability globally
• Explore the key stage-gates to a successful product life cycle, including what to do, when to do it, and how much investment is “worth it”
• Rethink how more effective cross-functional collaboration can advance your new product planning team